Professor Wu Yilong of our hospital won the Annual Achievement Award bestowed by Chinese Society of Clinical Oncology at the 24th Annual Meeting of Chinese Society of Clinical Oncology held on September 25 in Beijing. Academician Jia Fan from Chinese Academy of Sciences and Academician Yu Jinming from Chinese Academy of Engineering presented the award to Professor Wu Yilong.

For six years, Professor Wu Yilong has led 230 teams from 26 countries and regions around the world to work on using the third-generation targeted drug Osimertinib for postoperative adjuvant treatment of lung cancer, reducing 83% lung cancer recurrence or death risk, and rewriting the history that only adjuvant chemotherapy can be used after lung cancer surgery around the world for more than 20 years, thus benefiting millions of lung cancer patients and their families. The ADAURA study, published in the “New England Journal of Medicine”, is an example of the application of precision medicine to patients with early-stage lung cancer, and has established recurrence and transfer-free survival as an end point indicator for approving lung cancer indications, opening up a new road for clinical research on pan-cancer.

At present, this postoperative adjuvant treatment mode for EGFR-mutated lung cancer has been approved by more than 50 countries around the world and has become the standard treatment mode for this kind of lung cancer. China also approved this treatment mode in April this year.

Professor Wu Yilong made a speech titled “Non-Small-Cell Lung Cancer—Towards Cure” at the annual meeting. He explained how lung cancer clinicians have worked hard on lung cancer treatment and forged ahead step by step towards the goal of curing lung cancer. He further described some studies that are possible to make treatment strategies realize healing, which Guangdong Provincial People's Hospital and Guangdong Lung Cancer Institute are carrying out now and will carry out in the future.

Every year, Chinese Society of Clinical Oncology, with more than 30,000 members, selects an achievement made by Chinese researchers that has changed the clinical practice and grants it the Annual Achievement Award, which is a blockbuster award in the oncology clinical world. The research finding of Professor Wu Yilong has also been selected as a significant advance in Chinese medicine in 2020 by Chinese Academy of Medical Sciences.

Office of Lung Cancer Institute:  Gan Bin, Lin Jiachun